NESS-0327NESS 0327
Tricyclic pyrazole CB1 antagonist, presented as neutral; femtomolar Ki of 2003 revised to nanomolar in 2016 (4.2 to 126 nM depending on the assay).
Harm-reduction warning
No characterised human dose: animal / in vitro data only. Effect profile, safety margin and acute toxicity are not documented in human clinical practice. Extremely potent compound: severe effects, seizures and deaths reported in the literature.
C₂₄H₂₃Cl₃N₄O
CAS 494844-07-4
- Family
- ECS pharmacological toolAntagonist or inverse agonist
- Molar mass
- 489.80 g/mol
Updated on
In plain terms
NESS 0327 is a laboratory molecule that blocks the CB1 receptor, like rimonabant. In 2003 its authors credited it with extraordinary affinity; in 2016 part of the same group corrected these measurements to values in the nanomolar range. In animals it has been described as a "neutral" blocker. No study in humans was found.
Receptors and activity
Target network
- Blocks or inhibits
- Binds or modulates
The lower the cited value, the closer the target sits to NESS-0327: one ring per factor of 100. A target with no measured value stays on the edge.
Where these targets live
Where each target has been found in humans, according to the cited studies. The map shows the target, not an effect of NESS-0327.
CB1CB1 found in 7 regions of the body
- Basal gangliadenseMost dense in basal ganglia outflow nuclei1
- CerebellumdenseVery dense in the cerebellum1
- HippocampusdenseVery high concentrations in the hippocampus2
- AmygdaladenseHigh concentrations in the amygdala2
- CortexpresentPresent throughout the neocortex2
- Adipose tissuepresentExpressed in adipose tissue3
- GutpresentColonic epithelium, smooth muscle and plexus4
Map sources
- Herkenham M et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A, 1990 (new tab)
- Glass M et al. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience, 1997 (new tab)
- Engeli S et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes, 2005 (new tab)
- Wright K et al. Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology, 2005 (new tab)
Cited values
- CB1AntagonistKi = 4.2 nM · mouse73 out of 100
Lazzari et al., Eur J Med Chem 2016 (values read in ChEMBL, document CHEMBL3856211) (new tab) · [3H]CP-55940 displacement, whole mouse brain membranes (4.2 nM; a second determination at 8.18 nM); 126 nM at human CB1 (CHO cells); re-evaluation of 2016 which replaces the 350 fM value of 2003; read in ChEMBL (document CHEMBL3856211)
- CB2Binding (function not established)Ki = 55.7 nM · human54 out of 100
Lazzari et al., Eur J Med Chem 2016 (values read in ChEMBL, document CHEMBL3856211) (new tab) · [3H]-CP55,940 displacement, human CB2 transfected into CHO cells (55.7 nM; a second determination at 85.2 nM); 2016 re-evaluation; read in ChEMBL (document CHEMBL3856211)
Pharmacology
NESS 0327 is a tricyclic pyrazole CB1 receptor antagonist, a derivative of rimonabant whose skeleton is closed into a constrained system. In 2003, Ruiu and colleagues described it with an affinity of 350 fM for CB1 and a selectivity of more than 60,000-fold over CB2, values that for a time made it the highest-affinity CB1 antagonist published (Ruiu et al. 2003). These values did not survive reproduction: other laboratories measured nanomolar affinities, and in 2016 part of the original group itself reported a nanomolar rather than femtomolar Ki (Lazzari et al. 2016), with, according to ChEMBL, values of 4.2 to 8.18 nM at mouse CB1 and 126 nM at human CB1. It is still described as a CB1 antagonist: it did not stimulate [35S]GTPγS by itself, antagonised the effects of WIN 55,212-2 in vitro and in vivo (Ruiu et al. 2003) and, unlike rimonabant, does not suppress the constitutive activity of CB1; in the work of Meye and colleagues it reduced weight gain and food intake in laboratory animals like rimonabant, without the anxiety and reduced motivation for reward seen with that drug (Meye et al. 2013). These results are preclinical; no study in humans was found.
Key sources.
- Ruiu S et al. Synthesis and characterization of NESS 0327: a novel putative antagonist of the CB1 cannabinoid receptor. J Pharmacol Exp Ther, 2003 (new tab)PMID 12663689
- Lazzari P et al. A critical review of both the synthesis approach and the receptor profile of the 8-chloro-1-(2',4'-dichlorophenyl)-N-piperidin-1-yl-1,4,5,6-tetrahydrobenzo[6,7]cyclohepta[1,2-c]pyrazole-3-carboxamide and analogue derivatives. Eur J Med Chem, 2016 (new tab)PMID 27240274
- Meye FJ et al. Neutral antagonism at the cannabinoid 1 receptor: a safer treatment for obesity. Mol Psychiatry, 2013 (new tab)PMID 23070073
- PubChem, NESS-0327, CID 10435654 (identifiers and properties) (new tab)
History
- Source
- An entirely synthetic compound with no natural occurrence. It is known as an experimental pharmacology reagent; no clinical development was found in the sources consulted.
Origin
Research tool
No biological pathway: NESS 0327 is a synthetic compound of the tricyclic pyrazole class, unrelated to the plant cannabinoid pathway.
Legal framework
- European Union
The substance is not listed in the Annex to Council Framework Decision 2004/757/JHA (consolidated version of 12 January 2026), which lists the new psychoactive substances controlled at European Union level; control is a matter for national law. It is not listed in the schedules of the 1971 Convention on Psychotropic Substances (INCB Green List, 36th edition, 2025, text reviewed). No marketing authorisation was found.
- France
Not classified: NESS 0327 is not on the ANSM consolidated list of narcotics (updated 16/02/2026) and this tricyclic pyrazole (carboxamide) falls within none of the generic families of that list, the only pyrazole-3-carboxamide named being 5F-AB-FUPPYCA. No marketing authorisation was found.
Sources: EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA. Our method.
Classification
Family, origin and source verification
- Family
ECS pharmacological tool › Antagonist or inverse agonist
- Verification
Classification, sources and binding values checked on 20 October 2026; text read against its sources and Wikipedia.
- Wikipedia (English)
Article paired by the molecule's structure (InChIKey), revision read on 19 October 2026. Read as a second opinion, never cited as a source.
References
- Ruiu S et al. Synthesis and characterization of NESS 0327: a novel putative antagonist of the CB1 cannabinoid receptor. J Pharmacol Exp Ther, 2003 (new tab)PMID 12663689
- Lazzari P et al. A critical review of both the synthesis approach and the receptor profile of the 8-chloro-1-(2',4'-dichlorophenyl)-N-piperidin-1-yl-1,4,5,6-tetrahydrobenzo[6,7]cyclohepta[1,2-c]pyrazole-3-carboxamide and analogue derivatives. Eur J Med Chem, 2016 (new tab)PMID 27240274
- Meye FJ et al. Neutral antagonism at the cannabinoid 1 receptor: a safer treatment for obesity. Mol Psychiatry, 2013 (new tab)PMID 23070073
- PubChem, NESS-0327, CID 10435654 (identifiers and properties) (new tab)
Identifiers
Names
- Common name
- NESS 0327
- IUPAC name
- 12-chloro-3-(2,4-dichlorophenyl)-N-piperidin-1-yl-3,4-diazatricyclo[8.4.0.02,6]tetradeca-1(10),2(6),4,11,13-pentaene-5-carboxamide
- Other names
- NESS0327
Identifiers
- Formula
- C₂₄H₂₃Cl₃N₄O
- CAS
- 494844-07-4
- PubChem CID
- 10435654(new tab)
- InChIKey
- NCXBPZJQQSNIRA-UHFFFAOYSA-N
- SMILES
- C1CCN(CC1)
NC(= O) C2= NN(C3= C2CCCC4= C3C= CC(= C4) Cl) C5= C(C= C(C= C5) Cl) Cl
LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.